Efficacy of Auricular Neurostimulation for Children Adolescents and Young Adults With Chemotherapy Induced Nausea and Vomiting
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 18
- 试验地点
- 2
- 主要终点
- Baxter Retching Faces Scale
研究概览
简要总结
This study evaluates the efficacy of auricular percutaneous electrical nerve field stimulator in children, adolescents and young adults with chemotherapy induced nausea and vomiting.
详细描述
Chemotherapy induced nausea and vomiting (CINV) is a difficult to treat and potentially debilitating complication of chemotherapy. Nausea and vomiting are one of the most prevalent and problematic side effects associated with chemotherapy treatment, effecting numerous patients.
Autonomic nervous system (ANS) and the vagus nerve are important modulators of nausea and vomiting and are responsible for conveying visceral sensory information to the central nervous system responsible for nausea and vomiting. The aim of the study is to determine if stimulating a branch of the vagus nerve in the outer ear would reduce the frequency and severity of nausea and vomiting for patients undergoing chemotherapy treatment.
Subjects will be randomized to receive active vs sham (non-active) neurostimulation therapy which would be applied for maximum of 5 days at the onset of inpatient admission for moderate to severe emetogenic chemotherapy cycle. They will then cross over to the other group (active vs sham) during the admission of the following identical chemotherapy cycle. Nausea, vomiting, the need for additional antiemetic support and potential side effects will be monitored during the entire study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Prevention
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 4 Years 至 30 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects who are scheduled to be admitted for chemotherapy administration and who will have at least one additional cycle of the same chemotherapy
- •Chemotherapy regimens must include moderate and/or severe emetogenic chemotherapy
排除标准
- •Significant developmental delays that would prohibit participation
- •Infection or severe dermatological condition of ear
- •Uncontrolled or severe infection
- •No implanted electrical device is permitted
- •Pregnancy
- •Severe cardiopulmonary disease
- •Diagnosis of hemophilia or other bleeding disorders
- •Diagnosis psoriasis vulgaris
结局指标
主要结局
Baxter Retching Faces Scale
时间窗: From the date of baseline assessment up to 7 days after completion of intervention ( day 13)
Nausea severity assessed by pictorial nausea faces scale 0-10 (0=no nausea; 10= worse possible nausea) multiple times during hospitalization until discharge
Change in Rhodes Index of Nausea, Vomiting and Retching (INVR)
时间窗: From the date of baseline assessment and during the intervention (up to day 5)
Short 8 item questionnaire to assess severity of nausea, vomiting and retching symptoms
Assessment of Rescue Medication
时间窗: From the date of baseline assessment up to 7 days after completion of intervention ~ day 13
Number of rescue medications to be assessed on daily basis.
次要结局
未报告次要终点
研究者
Angela Steineck
Assistant Professor
Medical College of Wisconsin